ScholarWorks@Korea University College of Medicine: Yoon, Young Kyung

Detailed Information

Yoon, Young Kyung (윤영경)

Anam Hospital (Department of Infectious Diseases, Anam Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

COVID19:14||SARSCoV2:7||Acinetobacter baumannii:6||Infection control:6||Bacteremia:6||Korea:5||Methicillinresistant Staphylococcus aureus:4||Streptococcus pneumoniae:4||Risk factors:4||pneumonia:3||Endocarditis:3||risk factors:3||Mortality:3||Antibacterial agents:2||Liver Abscess:2||Accreditation:2||Risk factor:2||sepsis:2||Financial support:2||Candida:2||infection control:2||Candidemia:2||systematic review:2||Safety:2||Hepatitis A:2||Hepatitis B virus:2||Active surveillance:2||Empyema:2||Gramnegative bacteria:2||mortality:2||Pneumococcal infections:2||Clostridioides difficile:2||Klebsiella pneumoniae:2||Antibiotics:2||Surveillance:2||Pregnancy:2||Creactive protein:2||Antimicrobial resistance:2||Mycobacterium abscessus:2||Pseudomonas aeruginosa:2||Treatment outcome:2||Leadership:2||Neurosurgery:2||epidemiology:2||Escherichia coli:2||Vancomycinresistant enterococci:2||Clinical practice guidelines:1||Clinical prediction rule:1||Clinical severity:1||Clostridium difficile:1||Coinfection:1||Community treatment center:1||Communityacquired infections:1||Consensus:1||Coronavirus Disease 2019:1||Corticosteroid:1||Corynebacterium striatum:1||DHA1:1||Dendritic cells:1||Diabetes:1||Diagnosis:1||Digital health care monitoring system:1||Discitis:1||Disease Outbreaks:1||Disinfection:1||Drug resistance:1||ESBL:1||Echinocandins:1||Effectiveness:1||Efficacy:1||Electrochemical impedance spectroscopy:1||Emergency preparedness:1||Endogenous fungal endophthalmitis:1||Endophthalmitis:1||Enterococcus:1||Epidemiology:1||EpsteinBarr virus:1||Ertapenem:1||Erythrocyte:1||Extendedspectrum betalactamase:1||Fever of unknown origin:1||GENNOV:1||GRADE Approach:1||Gastrointestinal Carriage:1||Genotype:1||Guideline:1||Guidelines:1||Gummatous neurosyphilis:1||H1N1 subtype:1||HIV infection:1||HIV negative:1||Haemothorax:1||Health Resources:1||Health care facilities:1||Health care workers:1||Healthcare Crisis Resource Management:1||Healthcare Systems:1||Heart valve prosthesis:1||Hemolytic anemia:1||Hepatitis C virus:1||Hospitals:1||Hospitals, public:1||Huaiyangshan banyangvirus:1||Hyperlipidemia:1||Hypertriglyceridemia:1||Hypervirulent:1||ICUs:1||IDENTIFICATION:1||IL10:1||INFECTION:1||Immunocompromised host:1||Inappropriate:1||Infection Control:1||Infectious arthritis:1||Infective endocarditis:1||Influenza:1||Influenza A virus:1||Intensive care unit:1||Interrupted timeseries analysis:1||Intraabdominal infections:1||Intraabdominal Infections:1||Intraabdominal infections:1||Invasive aspergillosis:1||KLEBSIELLATREVISANII:1||Lactococcus garvieae:1||Lactococcus lactis:1||Latent syphilis:1||Legionella pneumophila:1||Length of stay:1||Leukocytes:1||Listeria monocytogenes:1||Living Evidence:1||MAB1843:1||MAPK:1||Malignancy:1||Measurement:1||Micafungin:1||Microbial:1||Middle east respiratory syndrome coronavirus:1||Miliary tuberculosis:1||Mucormycosis:1||Multidisciplinary:1||Multidisciplinary communication:1||Multidisciplinary communications:1||Multidrug resistance organism:1||Multidrugresistance:1||Multidrugresistant:1||Multidrugresistant bacteria:1||Neoagarooligosaccharides:1||Neonate:1||Neutropenia:1||Nocardia farcinica:1||Novel coronavirus disease 2019 (COVID19):1||Occupational exposure:1||Oral:1||Outbreak:1||Outbreaks:1||Outer membrane vesicles:1||PSEUDOMONASVESICULARIS:1||Pancreatitis:1||Pandemic:1||Pandemics:1||Pathogenesis:1||Performance:1||Personal protective equipment:1||Pharyngitis:1||Piperacillin/tazobactam:1||Posaconazole:1||Postexposure prophylaxis:1||PowerChek SFTSV Realtime PCR kit:1||Practice Guidelines as Topic:1||Practice guideline:1||Prevention:1||Procalcitonin:1||Prognostic factors:1||Prosthesisrelated infections:1||Pulmonary embolism:1||Pure red cell aplasia:1||Pyogenic:1||Quarantine:1||Resource:1||Respiratory virus:1||Rheumatoid arthritis:1||Rhinosinusitis:1||SARSCoV2 infection:1||SEPTICEMIA:1||SFTS virus:1||SFTSQS kit:1||SHV12:1||Sepsis:1||Septic shock:1||Severe Acute Respiratory Syndrome Coronavirus 2:1||Severe sepsis:1||Skull base:1||Spondylitis:1||Staffing:1||Stewardship:1||Streptococcus agalactiae:1||Streptococcus sanguinis:1||Suprasellar Tumor:1||Systematic Review:1||Terminally Ill:1||Th1 polarization:1||Thrombophlebitis:1||Timeseries analysis:1||Tonsillitis:1||Treatment:1||Treatment outcomes:1||Tuberculoma:1||Tuberculosis:1||Turnaround time:1||Vaccine:1||Virulence:1||Voriconazole:1||alanine aminotransferase:1||alphahemolysin:1||amphotericin B:1||antibacterial agent:1||antibiotics:1||antifungal therapy:1||antimicrobial peptide:1||antimicrobial peptides:1||antimicrobial stewardship programs:1||aspergillosis:1||bacteremia:1||biosensor:1||blood cultures:1||blood transfusion:1||bloodstream infections:1||brain abscess:1||cDNA microarray:1||candidaemia:1||carbapenem:1||carbapenem resistance:1||carbapenemresistance:1||carbapenemresistant Acinetobacter baumannii:1||casecontrol study:1||catheterrelated infections:1||cellular immunity:1||coinfection:1||colistin:1||colonization:1||combination therapy:1||communityacquired pneumonia:1||coronavirus disease 2019:1||cutaneous infection:1||diabetes:1||empyema:1||extracorporeal membrane:1||fecal microbiota transplantation:1||gastrointestinal microbiome:1||genotype:1||handshake:1||hepatitis A virus:1||humoral immunity:1||hyperglycemia:1||hypoglycemia:1||immunoassay:1||immunocompromised host:1||immunogenicity:1||infectious diseases:1||intensive care units:1||lung recovery:1||mRNA1273 vaccine:1||manpower and services:1||meropenem:1||metaanalysis:1||minimum inhibitory concentration:1||morbidity:1||moxifloxacin:1||multidrug resistant:1||multilocus sequence typing:1||multiplex:1||nanogel:1||neutralizing antibody:1||nosocomial infections:1||opportunistic infections:1||otolaryngology / ENT:1||outcome:1||outcomes:1||outer membrane vesicles:1||pituitary disorders:1||plasmid:1||prescription:1||procalcitonin:1||proteomics:1||pulmonary edema:1||pulmonary lymphomatoid granulomatosis:1||pulmonary tuberculosis:1||reactogenicity:1||respiratory medicine:1||respiratory viral infections:1||respiratory viruses:1||rhamnetin:1||sarilumab:1||septic shock:1||serotyping:1||severe sepsis:1||severity:1||spread:1||sputum:1||surface plasmon resonance (SPR):1||synergistic effect:1||tigecycline:1||timeseries analysis:1||tocilizumab:1||treatment outcome:1||ureteral obstruction:1||vaccine:1||viral diseases:1||voriconazole:1||다학제:1||리더십:1||의료기관 인증:1||재정적 지원:1||<p>A. baumannii</p>:1||항생제 내성:1||23valent pneumococcal vaccine:1||A20:1||Acquisition:1||Acute kidney injury:1||Acute pyelonephritis:1||Administration:1||Adverse Event:1||Amikacin:1||Amphotericin B:1||Anemia:1||Anidulafungin:1||AntiInfective agents:1||AntiSARSCoV2 monoclonal antibody:1||Antibiotic resistance:1||Antibiotic use:1||Antimicrobial Agents:1||Antimicrobial Consumption as a Key Component of Antimicrobial Stewardship Programs: a Meaningful Movement toward Evidencebased Antimicrobial Stewardship of Validated Outcome Measures:1||Antimicrobial Stewardship Programs:1||Antimicrobial Susceptibility:1||Antimicrobial drug resistance:1||Antimicrobial stewardship program:1||Antimicrobial utilization:1||Antiviral:1||Autoantibodies:1||Autonomic Dysfunction:1||BACTEREMIA:1||Bacteraemia:1||Baths:1||Biomarker:1||Biosensor:1||Bromocriptine:1||CHILD:1||COLONIZATION:1||COMBNOV:1||COX2:1||CRAB:1||Carbapenem:1||Carbapenem resistant:1||Casecontrol study:1||Ceftriaxone:1||Cell membrane:1||Central Fever:1||Chlorhexidine gluconate:1||Chronic kidney disease:1||Clinical pathways:1||

STATISTICS: Total View :12,656,180; Today View :2,459

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE